Literature DB >> 7622418

Ovarian teratomas in mice lacking the protooncogene c-mos.

Y Furuta1, Y Shigetani, N Takeda, K Iwasaki, Y Ikawa, S Aizawa.   

Abstract

Parthenogenesis has been suggested to be tightly coupled with development of ovarian teratomas. Indeed, ovarian tumors developed in c-mos-deficient female mice, which are characterized by the parthenogenetic activation of oocytes. The tumors appeared at a frequency of 30% between 4 and 8 months of age, and did not develop in younger or older mice. Most of the tumors were benign and consisted of multi-focal cysts most notably with mature ectodermal components, but also with mesodermal and endodermal components. One among 17 tumors observed consisted of extra-embryonic tissues alone, and two bore malignant components with metastasis to peritoneal organs. The results strongly suggest the involvement of c-mos mutations in human germ cell tumors.

Entities:  

Mesh:

Year:  1995        PMID: 7622418      PMCID: PMC5920872          DOI: 10.1111/j.1349-7006.1995.tb02432.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  26 in total

1.  Granulosa cell deficient follicles: occurrence, structure, and relationship to ovarian teratocarcinogenesis in strain LT/Sv mice.

Authors:  J J Eppig
Journal:  Differentiation       Date:  1978       Impact factor: 3.880

2.  Ovarian teratomas in mice are derived from oocytes that have completed the first meiotic division.

Authors:  J J Eppig; L P Kozak; E M Eicher; L C Stevens
Journal:  Nature       Date:  1977-10-06       Impact factor: 49.962

3.  A virus-induced rhabdomyosarcoma of mice.

Authors:  J B Moloney
Journal:  Natl Cancer Inst Monogr       Date:  1966-09

4.  The epidemiologic pathology of ovarian cancer.

Authors:  J W Berg; S M Baylor
Journal:  Hum Pathol       Date:  1973-12       Impact factor: 3.466

5.  Comparative pathology of ovarian neoplasms. 3. Germ cell tumours of canine, bovine, feline, rodent and human species.

Authors:  L P Dehner; H J Norris; F M Garner; H B Taylor
Journal:  J Comp Pathol       Date:  1970-04       Impact factor: 1.311

6.  Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element.

Authors:  G Rechavi; D Givol; E Canaani
Journal:  Nature       Date:  1982-12-16       Impact factor: 49.962

7.  Developmental potential of LT/Sv parthenotes derived from oocytes matured in vivo and in vitro.

Authors:  J J Eppig
Journal:  Dev Biol       Date:  1978-07       Impact factor: 3.582

8.  Germ cell tumours of the ovary--a histopathological study.

Authors:  S P Tyagi; A Madan; S Mohsin; S Hameed
Journal:  Indian J Pathol Microbiol       Date:  1978-04       Impact factor: 0.740

9.  Malignant germ cell tumors of the ovary.

Authors:  R J Kurman; H J Norris
Journal:  Hum Pathol       Date:  1977-09       Impact factor: 3.466

10.  A characterization of cytostatic factor activity from Xenopus eggs and c-mos-transformed cells.

Authors:  I Daar; R S Paules; G F Vande Woude
Journal:  J Cell Biol       Date:  1991-07       Impact factor: 10.539

View more
  4 in total

Review 1.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

2.  Inactivation of Retinoblastoma Protein (Rb1) in the Oocyte: Evidence That Dysregulated Follicle Growth Drives Ovarian Teratoma Formation in Mice.

Authors:  Qi-En Yang; So I Nagaoka; Ivy Gwost; Patricia A Hunt; Jon M Oatley
Journal:  PLoS Genet       Date:  2015-07-15       Impact factor: 5.917

3.  MC4R mutant mice develop ovarian teratomas.

Authors:  Abdullah An Naser; Takehiro Miyazaki; Jun Wang; Shuji Takabayashi; Theeranukul Pachoensuk; Toshinobu Tokumoto
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.379

4.  Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas.

Authors:  K A de Foy; S A Gayther; W H Colledge; S Crockett; I V Scott; M J Evans; B A Ponder
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.